Published in Oncogene on January 30, 2017
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst (1973) 11.26
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res (1973) 4.65
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature (2015) 3.24
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng (2003) 3.04
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med (1984) 2.22
Deconvolution microscopy. Adv Biochem Eng Biotechnol (2005) 2.16
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
Ewing's sarcoma. A critical analysis of 165 cases. J Bone Joint Surg Am (1961) 1.75
The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet (2014) 1.74
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol (2011) 1.70
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov (2014) 1.63
Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene (2010) 1.62
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst (2011) 1.55
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol (2014) 1.50
The genomic landscape of pediatric Ewing sarcoma. Cancer Discov (2014) 1.46
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages. J Immunol Methods (2007) 1.35
Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle (2006) 1.27
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene (2012) 1.20
The biology of ewing sarcoma. ISRN Oncol (2013) 1.19
Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. Cancer Cell (2015) 1.08
Automated whole animal bio-imaging assay for human cancer dissemination. PLoS One (2012) 1.05
Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res (2010) 1.05
αTAT1 catalyses microtubule acetylation at clathrin-coated pits. Nature (2013) 1.03
SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene (2010) 0.99
Sarcomas. Pediatr Clin North Am (2015) 0.97
MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene (2013) 0.97
The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. Exp Cell Res (2004) 0.97
A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene (2000) 0.93
ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. Genes Cancer (2013) 0.91
Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer (2009) 0.90
Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res (2013) 0.89
Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res (2014) 0.88
The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes Cancer (2012) 0.88
Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res (2014) 0.87
Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells. PLoS One (2013) 0.87
Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J Pathol (2014) 0.87
Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell (2014) 0.83
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol (2012) 0.82
The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma. Int J Oncol (2013) 0.80
Low-grade tubular myxoid renal tumors: a clinicopathological study of 3 cases. Int J Surg Pathol (2004) 0.78